Navigation Links
Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency

WAYLAND, Mass., Aug. 3 , 2011) /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The contract totals $2.9 million over 2 years provided that key milestones are achieved. Should Avaxia's program meet its anticipated endpoints at the end of this contract, the company hopes to pursue future opportunities with BARDA.  

Dr. Barbara Fox, Avaxia's CEO, commented, "We are very pleased to receive this contract and are proud to be working on this program related to our country's national defense. With this funding, we will be advancing our oral antibody product through the key efficacy studies needed to support the product's use as a nuclear threat countermeasure. This contract will permit us to complete the pre-clinical pharmacology studies for this potential therapy. We look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.

This award provides Avaxia with a new drug development program that is of significant benefit to the company.  Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease.  Also, should the project meet its targets, the manufacturing and sales of a radiation mitigation drug will increase the commercial opportunities for the company."

About BARDA:  The Biomedical Advanced Research and Development Authority (BARDA), is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.  BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, stockpile acquisition, innovation, and manufacturing infrastructure building of the necessary vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health medical emergencies including chemical, biological, radiological, and nuclear threats, and pandemic influenza, and emerging infectious diseases. For additional information, visit

About Avaxia Biologics, Inc.:  Avaxia Biologics ( is an early stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, oral mucositis, celiac disease, diabetes and obesity.

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Canada Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. China Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
5. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
9. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
Post Your Comments:
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015  Following an ... (NASDAQ: OGXI ) announced today that its Phase ... interim futility analysis of the intent-to-treat (ITT) population. In ... identified by the DMC. Both the DMC and OncoGenex ... expected in the second half of 2016, depending on ...
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Hospital Tampa is the first health care provider in the region to offer the ... is a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult ... least 40 to 45 kg, or a BMI of at least 35 to 39.9 kg ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Dr. Paul Vitenas, ... Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician Practice ... best among the many elite aesthetic physicians honored by the industry publication. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Annual 2015 Golden Bridge Business Awards under the New Products and Services category ... web based sample management software that helps labs organize data and ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been awarded a fixed price per sprint agile development contract to support ... $34 million over five years, provides software engineering, infrastructure, as well as operations ...
Breaking Medicine News(10 mins):